Table 3.
Signal scores for JAK inhibitors-associated PE
| JAK inhibitor | Total (n) | Cases (n) | ROR (95% CI) | IC (95% CI) |
|---|---|---|---|---|
| JAK inhibitors | 6631 | 41 | 1.71* (1.26–2.34) | 0.74 (− 0.29 to 1.78) |
| Tofacitinib | 2431 | 13 | 1.48 (0.85–2.55) | 0.50 (− 1.28 to 2.29) |
| Ruxolitinib | 1513 | 8 | 1.46 (0.73–2.92) | 0.47 (− 1.76 to 2.69) |
| Baricitinib | 1338 | 14 | 2.91* (1.71–4.93) | 1.35 (− 0.38 to 3.08) |
| Peficitinib | 651 | 2 | 0.84 (0.21–3.39) | − 0.17 (− 4.01 to 3.68) |
| Upadacitinib | 580 | 5 | 2.39 (0.99–5.76) | 0.95 (− 1.78 to 3.68) |
| Filgotinib | 233 | 0 | – | – |
| Abrocitinib | 30 | 0 | – | – |
JA janus kinase, PE pulmonary embolism, ROR reported odds ratio, IC information component
*The adverse events are detected as signals